Market Overview - On August 18, Hong Kong's three major indices showed mixed results, with the Hang Seng Index down 0.37% at 25,176.85 points, the Hang Seng Tech Index up 0.65% at 5,579.18 points, and the Hang Seng China Enterprises Index down 0.06% at 9,033.68 points [1] - The pharmaceutical sector remained strong, while cyclical stocks were generally weak. Notable stock movements included BYD up over 0.5%, Alibaba and Xiaomi both up nearly 0.5%, Tencent down over 0.5%, and Kuaishou down nearly 1.5% [1] - The Hang Seng Tech Index ETF (513180) rose by 1.06% [1] Southbound Capital - On August 18, southbound capital recorded a net inflow of 1.386 billion HKD, bringing the total net inflow for the year to 940.308 billion HKD, significantly exceeding last year's total [1] U.S. Market Performance - U.S. stock indices showed mixed results overnight, with the Dow Jones down 0.08%, S&P 500 down 0.01%, and Nasdaq up 0.03%. Notable declines included Sherwin-Williams and Amgen, both down over 1% [1] - Chinese concept stocks had mixed performances, with Xunlei up over 37% and Niu Technologies down nearly 10%. The Nasdaq Golden Dragon China Index rose by 0.12% [1] Earnings Reports - Recently, the Hong Kong stock market entered a period of concentrated earnings disclosures. On August 18, Leap Motor reported a net profit of 30 million CNY for the first half of the year, becoming the second Chinese electric vehicle manufacturer to achieve semi-annual profitability [2] - Leap Motor raised its annual sales target to between 580,000 and 650,000 units, with a goal of challenging 1 million units in sales next year [2] Short Selling Data - On August 18, a total of 638 Hong Kong stocks were short-sold, with total short selling amounting to 33.484 billion HKD. The top three stocks by short selling amount were Tencent Holdings at 1.598 billion HKD, Xiaomi Group at 1.255 billion HKD, and Alibaba at 1.135 billion HKD [3] Institutional Insights - According to Guotai Junan, the acceleration of AI applications is benefiting Hong Kong's tech sector, which is seen as a main investment theme. The AI industry is expected to grow rapidly due to technological and policy catalysts [4] - The State Council's recent approval of the "Artificial Intelligence +" action plan aims to promote large-scale commercial applications of AI, which could enhance the competitive edge of Hong Kong's tech leaders [4] - The Hong Kong market is also expected to benefit from strengthened dividend policies and low interest rates, making new consumption and innovative pharmaceutical assets attractive compared to A-shares [4] Hong Kong ETFs - The Hong Kong Consumption ETF (513230) focuses on e-commerce and new consumption sectors, which are relatively scarce compared to A-shares [5] - The Hang Seng Tech Index ETF (513180) includes core AI assets in China, representing a scarcity of tech leaders compared to A-shares [5]

Core Viewpoint - Company has raised its adjusted net profit forecast for China Biopharmaceutical (01177) for 2025/2026 by 16.9%/17.2% to CNY 4.47 billion/CNY 4.92 billion, driven by operational efficiency improvements and increased dividend income [1] Financial Performance - In 1H25, the company reported revenue of CNY 17.575 billion, a year-on-year increase of 10.7%; net profit attributable to shareholders was CNY 3.389 billion, up 12.3%; adjusted net profit reached CNY 3.088 billion, a significant increase of 101.1%, exceeding expectations due to better-than-expected revenue from innovative products and dividend income [2] Growth Drivers - Innovative products drove double-digit revenue growth in 1H25, with innovative product revenue reaching CNY 7.799 billion, a year-on-year increase of 27.2%, accounting for 44.4% of total revenue (up 5.8 percentage points year-on-year); oncology drug revenue was CNY 6.694 billion (up 24.9%), and surgical analgesics revenue was CNY 3.105 billion (up 20.2%); the company expects innovative product revenue to exceed 50% of total revenue in 2025 [3] Management Efficiency - The company has improved management efficiency, achieving a gross margin of 82.5% (up 0.4 percentage points year-on-year) and a sales management expense ratio of 42.9% (down 0.2 percentage points year-on-year); the number of marketing personnel decreased by 8.6% year-on-year, while per capita output of marketing personnel increased by 21.8% [4] Strategic Acquisitions - Following the acquisition of Lixin Pharmaceutical, the company has accelerated its innovation pipeline focusing on oncology, liver disease metabolism, respiratory infections, and surgical analgesics; it is advancing clinical trials for various cancer treatments, including lung cancer and breast cancer, and expects to see more effective data and overseas business development transactions [5]

香精及食品配料业务承压明显 香精及食品配料业务在报告期内面临较大挑战，销售收入同比下滑8.6%至约5.96亿元，营运盈利更是大 幅减少86.4%至约1876.6万元。营运盈利率从去年同期的21.1%下滑至3.2%，降幅达17.9个百分点。这一 显著下滑主要源于产品销售结构变化以及终止股权激励计划确认的约7005.6万元费用。 在细分领域中，烟用香精受到主要客户需求变化、采购政策调整和自主调香等因素影响，销售出现下 滑。为应对这一挑战，集团积极开拓东南亚和中东市场的烟用香精需求，并搭建相应的渠道和产品库。 食品用香精方面，集团强化了微波干燥、萃取、包埋技术和香基模块建设方面的技术能力，以提升产品 和服务的竞争力。 日化香精业务则通过对全球市场趋势的研究，强化了在口腔护理、空间香氛等细分市场的产品和服务能 力。随着可持续发展因素在日化用产品中的重要性日益凸显，集团投入资金寻找独特、安全、环保的天 然香原料，并与国内外大学合作开展香精的气味、情绪价值、调香技术方面的研究。 烟用原料业务实现强劲增长 烟用原料业务在报告期内表现突出，销售收入约2.38亿元，同比增长45.3%，占集团总收入约14.7%。板 块营运盈利约 ...

王爷说财经讯：孙正义抢先特朗普一步，日本科技巨头软银出手了！宣布投资20亿美元给英特尔！自此，软银成为英特尔第5大股东！ 那么为什么软银要投资这么多钱给英特尔？未来英特尔又会如何？一起来看看！ 值得一提的是，就在上周，美国总统——特朗普曾公开呼吁英特尔CEO陈立武应该辞职，随后陈立武便赴白宫与特朗普会面，市场也传出特朗普考虑入股英 特尔的消息。 至于为什么美国特朗普政府要入股英特尔，王爷说财经之前就分析过，这主要原因包括：英特尔是美国芯片工业的"最后堡垒"，所以特朗普的"美国优先"战 略需要它扛起大旗，另外还有就是特朗普的政治考虑！【详情见我们之前的视频文章《 芯片战升级！特朗普政府考虑入股英特尔，这背后藏着美国什么野 心？》】 与此同时，据美国CNBC报道，英特尔至今尚未能从先进半导体的AI热潮中受益，英特尔股价去年累跌60％，创该公司上市以来最差的年度表现，不过，今 年截至美股周一收盘，该股于2025年累计上涨18％。 8月19日消息，英特尔与软银宣布，软银将以每股23美元购买英特尔普通股，共预计投入20亿美元，这笔投资被视为对英特尔的信心表态。 而这笔投资也使得软银成为英特尔的第五大股东。 受此激励，英 ...

Core Viewpoint - China Hongqiao Group reported a strong performance in the first half of 2025, with significant growth in revenue, gross profit, and net profit, indicating robust operational resilience and effective risk management strategies [1][3][4]. Financial Performance - The company achieved a revenue of 81.04 billion yuan, a year-on-year increase of 10.1%, with gross profit and net profit reaching 20.805 billion yuan and 12.361 billion yuan, respectively, reflecting growth rates of 16.9% and 35% [1][4]. - The basic earnings per share were 1.314 yuan, marking a 36% increase compared to the previous year [1]. Business Segments - The three core business segments—aluminum alloy, alumina, and aluminum processing—saw revenue growth of 5.2%, 27.5%, and 6.5%, respectively, with total sales contributions of 64%, 25.5%, and 10% [3]. - Sales volumes for aluminum alloy, alumina, and aluminum processing were approximately 2.906 million tons, 6.368 million tons, and 392,000 tons, showing year-on-year increases of 2.4%, 15.6%, and 3.5% [3]. Strategic Initiatives - The company is focused on building an integrated upstream and downstream industrial chain, actively securing overseas bauxite resources, and enhancing its global cooperative model [3]. - China Hongqiao is committed to sustainable development, emphasizing low-carbon transformation and integrating advanced technologies into daily operations [3][4]. Green Energy Strategy - The company is advancing its green energy strategy by diversifying its power supply model and increasing the proportion of clean energy [4]. - A phased approach to carbon reduction is being implemented, aiming to achieve net-zero emissions in collaboration with stakeholders across the value chain [4]. Financial Stability and Market Confidence - The company successfully issued two bonds totaling 600 million USD, with a subscription rate of 12 times, and a 300 million USD convertible bond with an 8 times subscription rate and a low interest rate of 1.5% [4]. - China Hongqiao's subsidiaries received AAA credit ratings, and the company issued short-term financing bonds and medium-term notes worth 8.1 billion yuan, reflecting strong investor confidence [4]. Market Outlook - Despite uncertainties in the global economic landscape, demand for aluminum remains robust, and the company is expected to benefit from continued growth in both volume and price in the second half of the year [5]. - A new share buyback plan has been announced, aiming to repurchase at least 3 billion HKD worth of shares over the next nine months, which is anticipated to boost market confidence and drive up the company's market value [5].

Group 1 - Company Gilead Sciences-B (01672) announced a placement and subscription agreement on August 19, 2025, involving the sale of 52.4 million shares at a price of HKD 16.45 per share [1][2] - The total number of shares being placed represents approximately 5.44% of the company's issued share capital as of the announcement date, excluding treasury shares [2] - The subscription involves the issuance of 28.82 million new shares, which accounts for about 2.90% of the enlarged share capital post-placement and subscription [2] Group 2 - The placement price of HKD 16.45 per share reflects a discount of approximately 9.9% compared to the closing price of HKD 18.26 on August 18, 2025 [2] - Following the completion of the placement and subscription, the selling shareholder's stake will decrease from approximately 53.38% to 49.45% of the issued share capital, excluding treasury shares [2] - The net proceeds from the subscription are expected to be around HKD 468 million, with about 90% allocated for clinical trial development related to obesity treatments and 10% for general corporate purposes [2]

详见PDF ...

香港联交所最新资料显示，8月18日，信义玻璃(00868)股东将股票由花旗银行转入香港上海汇丰银行， 转仓市值13.37亿港元，占比3.46%。 信义玻璃公布，2025年8月6日公司耗资约4973.25万港元回购622.7万股股份。 ...

Core Viewpoint - The company, Gilead Sciences-B (01672), has entered into a placement and subscription agreement to sell and issue shares, which will result in a significant change in shareholding structure and raise funds for clinical trials and operational needs [1][2]. Group 1: Share Placement and Subscription Details - The total number of shares to be placed is 52.4 million, representing approximately 5.44% of the company's issued share capital as of the announcement date [2]. - The subscription involves 28.82 million new shares, accounting for about 2.90% of the enlarged issued share capital post-placement and subscription [2]. - The placement price is set at HKD 16.45 per share, which is a discount of approximately 9.9% compared to the closing price of HKD 18.26 on the last trading day [2]. Group 2: Shareholding Changes - Following the completion of the placement and subscription, the selling shareholder's stake will decrease from approximately 53.38% to 49.45% of the issued share capital [2]. - The total shareholding percentage of the controlling shareholder will reduce from about 62.21% to approximately 58.03% after the issuance of the new shares [2]. Group 3: Use of Proceeds - The net proceeds from the subscription are expected to be around HKD 468 million after deducting commissions and estimated expenses [2]. - Approximately 90% of the net proceeds is intended for the development of clinical trials related to subcutaneous and oral peptide candidates for obesity [2]. - The remaining 10% of the net proceeds is suggested for working capital and other general corporate purposes [2].

香港联交所最新资料显示，8月18日，谢瑞麟(00417)股东将股票由香港上海汇丰银行转入时富证券，转 仓市值1.21亿港元，占比72.53%。 谢瑞麟2025年3月31日止年度末期业绩显示，营业额约17.12亿港元，同比减少35.5%;公司拥有人应占亏 损约1.98亿港元，同比收窄47.15%。 ...